Coherus Oncology, Inc. (CHRS) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-03-09

How it makes money

Revenue grows when patients are diagnosed and insurers agree to cover the cost of treatment.

The company earns money by selling LOQTORZI to treat nasopharyngeal carcinoma.

Profitability is driven by the size of the patient market and the ability to secure reimbursement from third-party payers.

What protects it: the moat

It is the only FDA-approved immune checkpoint inhibitor for these indications available in the U.S.

Management claims the company's advantage is that LOQTORZI is currently the only commercially available immune checkpoint inhibitor approved by the FDA for these specific cancer treatments in the United States.

What growth costs

It must spend heavily on clinical studies and manufacturing to advance its pipeline.

To grow, the company reinvests in nonclinical and clinical development for its pipeline candidates.

It is also onshoring its manufacturing processes to the United States.

What could damage it

A loss of insurance reimbursement would destroy the revenue needed to fund its operations.

If third-party payers do not provide adequate reimbursement for LOQTORZI, the company may fail to generate sufficient revenue to support its expensive research and development programs.

About Coherus Oncology, Inc.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Other companies in Biotechnology